Nanotechnology Now

Our NanoNews Digest Sponsors


Heifer International

Wikipedia Affiliate Button


DHgate

Home > Press > Arrowhead Appoints Michael S. Perry, DVM, Ph.D. to Board of Directors

Abstract:
Arrowhead Research Corporation (NASDAQ: ARWR), a nanomedicine company with development programs in oncology and obesity, announced today that it has appointed Michael S. Perry, Hon BSc, DVM, Ph.D., to its board of directors.

Arrowhead Appoints Michael S. Perry, DVM, Ph.D. to Board of Directors

Pasadena, CA | Posted on December 19th, 2011

Dr. Perry brings over 25 years of successful biotechnology and pharmaceutical management and research and development experience, as well as healthcare investing expertise to Arrowhead. He has a proven track record in research and development innovation, with emphasis on product development and approval, strategic portfolio management, integration of company mergers and acquisitions, business development, and driving shareholder value. Dr. Perry is currently a Venture Partner at Bay City Capital, a life science focused investment fund that manages seven funds, representing approximately $1.6 billion in capital. He is also President and Chief Medical Officer of Poniard Pharmaceuticals (PARD: NASDAQ).

"Mike's knowledge and experience in drug development will be instrumental as we progress our lead candidates through clinical development," said Dr. Christopher Anzalone, President and Chief Executive Officer. "In addition, his expertise in strategic business development transactions and product assessment will be important as we continue to execute on our partnership and broader business strategies."

Dr. Perry has filed over 50 investigational new drug applications, and over 30 new drug applications and biologic license applications, for a number of companies across the globe. His previous roles include Chief Development Officer of VIA Pharmaceuticals and Founder and Chief Executive Officer of Extropy Pharmaceuticals. He was also Chief Executive Officer of Pharsight, SyStemix and Genetic Therapy, serving as a director on each of the companies' boards. Prior to these positions, Dr. Perry was Global Head of Research and Development for Baxter BioScience, Vice President of Novartis Pharma, and Vice President of Syntex Corporation. He currently serves as a member of the board of directors of AmpliPhi Biosciences Corporation (APHB.PK).

"I look forward to serving on Arrowhead's Board of Directors," said Perry. "The company has emerged as a leader in the development of RNAi therapeutics with access to a broad suite of intellectual property and novel delivery solutions. I look forward to contributing to Arrowhead's continuing future success as an independent director."

Dr. Perry holds an Honors BSc in Engineering/Physics from the University of Guelph, a DVM from the Ontario Veterinary College, and a Ph.D. in Biomedical Pharmacology from the University of Guelph. He is a Fellow of the Royal College of Veterinary Surgeons and a graduate of the Executive International Management Program at Harvard Business School.

####

About Arrowhead Research Corporation
Arrowhead Research Corporation is a clinical stage nanomedicine company developing innovative therapies at the interface of biology and nanoengineering. Arrowhead's world-class capabilities and intellectual property covering nucleic acid delivery, siRNA chemistry, and tissue targeting allow it to design and develop therapeutic agents for a wide range of diseases. The company's lead products include CALAA-01, an oncology drug candidate based on the gene silencing RNA interference (RNAi) mechanism, and Adipotide™, an anti-obesity peptide that targets and kills the blood vessels that feed white adipose tissue. Arrowhead is leveraging its proprietary Dynamic Polyconjugate™ (DPC), Liposomal Nanoparticle (LNP), and RONDEL™ delivery platforms to support its own pipeline of preclinical and clinical candidates and to secure external partnerships and collaborations with biotech and pharmaceutical companies. For more information, please visit
www.arrowheadresearch.com.


Safe Harbor Statement Under the Private Securities Litigation Reform Act:

This news release contains forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. These statements are based upon our current expectations and speak only as of the date hereof. Our actual results may differ materially and adversely from those expressed in any forward-looking statements as a result of various factors and uncertainties, including the future success of our scientific studies, our ability to successfully develop drug candidates, the timing for starting and completing clinical trials, rapid technological change in our markets, and the enforcement of our intellectual property rights. Arrowhead Research Corporation's most recent Annual Report on Form 10-K and subsequent Quarterly Reports on Form 10-Q discuss some of the important risk factors that may affect our business, results of operations and financial condition. We assume no obligation to update or revise forward-looking statements to reflect new events or circumstances.

For more information, please click here

Contacts:
Investor Relations Contact:
The Trout Group, LLC
Marcy Nanus
646-378-2927

Copyright © Arrowhead Research Corporation

If you have a comment, please Contact us.

Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.

Bookmark:
Delicious Digg Newsvine Google Yahoo Reddit Magnoliacom Furl Facebook

Related News Press

News and information

UK NANOSAFETY GROUP publishes 2nd Edition of guidance to support safe working with nanomaterials May 30th, 2016

Fast, stretchy circuits could yield new wave of wearable electronics May 30th, 2016

Automating DNA origami opens door to many new uses: Like 3-D printing did for larger objects, method makes it easy to build nanoparticles out of DNA May 30th, 2016

Simple attraction: Researchers control protein release from nanoparticles without encapsulation: U of T Engineering discovery stands to improve reliability and fabrication process for treatments to conditions such as spinal cord damage and stroke May 28th, 2016

Nanomedicine

Automating DNA origami opens door to many new uses: Like 3-D printing did for larger objects, method makes it easy to build nanoparticles out of DNA May 30th, 2016

Simple attraction: Researchers control protein release from nanoparticles without encapsulation: U of T Engineering discovery stands to improve reliability and fabrication process for treatments to conditions such as spinal cord damage and stroke May 28th, 2016

Scientists illuminate a hidden regulator in gene transcription: New super-resolution technique visualizes important role of short-lived enzyme clusters May 27th, 2016

Supercrystals with new architecture can enhance drug synthesis May 24th, 2016

Announcements

UK NANOSAFETY GROUP publishes 2nd Edition of guidance to support safe working with nanomaterials May 30th, 2016

Fast, stretchy circuits could yield new wave of wearable electronics May 30th, 2016

Automating DNA origami opens door to many new uses: Like 3-D printing did for larger objects, method makes it easy to build nanoparticles out of DNA May 30th, 2016

Simple attraction: Researchers control protein release from nanoparticles without encapsulation: U of T Engineering discovery stands to improve reliability and fabrication process for treatments to conditions such as spinal cord damage and stroke May 28th, 2016

Appointments/Promotions/New hires/Resignations/Deaths

Park Systems Global Expansion in AFM Market Includes Appointment of New Executives April 23rd, 2016

GLOBALFOUNDRIES Adds Alain Mutricy as Head of Product Management Group March 3rd, 2016

George Clark Named Chief Financial Officer and Associate Laboratory Director for Business Services at Brookhaven Lab February 24th, 2016

NSS Pays Tribute to Late NSS Governor Dr. Marvin Minsky, A Pioneer in Artificial Intelligence February 11th, 2016

NanoNews-Digest
The latest news from around the world, FREE




  Premium Products
NanoNews-Custom
Only the news you want to read!
 Learn More
NanoTech-Transfer
University Technology Transfer & Patents
 Learn More
NanoStrategies
Full-service, expert consulting
 Learn More











ASP
Nanotechnology Now Featured Books




NNN

The Hunger Project







Car Brands
Buy website traffic